Dabur approves interim dividend for FY2026-27, sets November 10 record date
Key Facts
The Bombay Stock Exchange’s announcements list on November 4, 2026, described a Dabur India board meeting as approving unaudited financial and segment results for the quarter and half-year ended September 30, and declaring an interim dividend for FY2026-27. The filing description said the announcement covered both consolidated and standalone results. The company set November 10, 2026, as the record date for shareholders eligible for the dividend, subject to board approval at its meeting. The dividend amount and payment date could not be verified in a reliable, publicly available source. Verified figures for revenue or profit for the period ended in September were also unavailable in the information reviewed.
The list groups the quarter and half-year results in one disclosure, but its announcement description provides no detailed financial figures attributable to the September period. The verified information here therefore does not allow for measuring changes in revenue or profit, or determining whether the company met its earlier expectations. The record date falls days after the board meeting and identifies the shareholders on record that day for the interim dividend. The dividend amount and payment terms could not be confirmed from the open sources reviewed. The November 4 announcement remains the current development, while first-quarter data provide a separate historical reference.
In an earlier update ahead of its results, Dabur expected growth in India’s fast-moving consumer goods sector to accelerate to double digits, according to a Financial Express report. The company also expected double-digit growth in its home and personal care business, and high double-digit growth in hair oils and shampoos. It said perfumed hair oils and coconut oil were among the categories supporting those expectations. These were estimates made before the quarter’s results, not reported figures for the period ended in September. The available evidence does not allow those expectations to be compared with published actual results for the same period.
The company said inflation affected operating margins during the quarter, according to the Financial Express report. It said calibrated price increases and cost-saving initiatives offset part of the impact. The earlier update thus linked margin pressure with the company’s efforts to mitigate it, without quantifying the effect. The available information contains no verified figure for the operating margin in the September results or the size of any change. This remains a description of what the company said before announcing results, not a final financial outcome for the quarter.
Dabur’s first-quarter results for FY2026-27 provide an earlier reference for the company’s performance. In July, it reported consolidated net profit of 591 crore rupees, up 15%, and consolidated revenue of 3,764 crore rupees, up 10.6%. These figures are for the quarter ended June 30, not the quarter ended September 30. By segment, home and personal care grew 12.3% in the first quarter, compared with 7.2% for food and beverages and 5.5% for healthcare. The figures help put the latest announcement in the context of earlier performance, but they do not represent the full half-year results or the second quarter alone. The verified evidence contained no newer figures allowing a direct comparison with the September results.
In the first quarter, Dabur also said demand growth in India’s rural markets was 6.2%, compared with 4.6% in urban markets, marking the eighth consecutive quarter in which rural areas outperformed. This measure relates to the period ended in June and does not describe demand trends in the September quarter. The company’s international business also grew 15.5% in rupee terms in the first quarter, with its businesses in Bangladesh and Egypt growing 34.3% and 28.4%, respectively. These figures reflect performance in international markets in the earlier period, with growth rates varying by market. No published figures for the quarter and half-year results approved on November 4 could be confirmed in the available evidence.